{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:19:05Z","timestamp":1792801145667,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Forschungskommission of the Medical Faculty of the Heinrich-Heine University D\u00fcsseldorf","id":[{"id":"https:\/\/ror.org\/024z2rq82","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12974-018-1111-y","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T04:04:00Z","timestamp":1520395440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model"],"prefix":"10.1186","volume":"15","author":[{"given":"Michael","family":"Dietrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Helling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Heskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Issberner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zippora","family":"Kohne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"K\u00fcry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Berndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7987-658X","authenticated-orcid":false,"given":"Philipp","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"1111_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502\u201317.","journal-title":"Lancet"},{"key":"1111_CR2","first-page":"164608","volume":"2011","author":"J Witherick","year":"2010","unstructured":"Witherick J, Wilkins A, Scolding N, Kemp K. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Dis. 2010;2011:164608.","journal-title":"Autoimmune Dis"},{"key":"1111_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0165-5728(98)00175-1","volume":"92","author":"A van der Goes","year":"1998","unstructured":"van der Goes A, Brouwer J, Hoekstra K, Roos D, van den Berg TK, Dijkstra CD. Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J Neuroimmunol. 1998;92:67\u201375.","journal-title":"J Neuroimmunol"},{"key":"1111_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000363515","volume":"72","author":"P Wang","year":"2014","unstructured":"Wang P, Xie K, Wang C, Bi J. Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis. Eur Neurol. 2014;72:249\u201354.","journal-title":"Eur Neurol"},{"key":"1111_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bbadis.2010.06.011","volume":"1812","author":"J van Horssen","year":"2011","unstructured":"van Horssen J, Witte ME, Schreibelt G, de Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta. 2011;1812:141\u201350.","journal-title":"Biochim Biophys Acta"},{"key":"1111_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nm.2324","volume":"17","author":"I Nikic","year":"2011","unstructured":"Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2011;17:495\u20139.","journal-title":"Nat Med"},{"key":"1111_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0165-5728(94)00154-G","volume":"56","author":"SR Ruuls","year":"1995","unstructured":"Ruuls SR, Bauer J, Sontrop K, Huitinga I, A\u2019t Hart B, Dijkstra CD. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol. 1995;56:207\u201317.","journal-title":"J Neuroimmunol"},{"key":"1111_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00415-004-0348-9","volume":"251","author":"Y Gilgun-Sherki","year":"2004","unstructured":"Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol. 2004;251:261\u20138.","journal-title":"J Neurol"},{"key":"1111_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fcell.2016.00063","volume":"4","author":"K Lepka","year":"2016","unstructured":"Lepka K, Berndt C, Hartung H-P, Aktas O. Redox events as modulators of pathology and therapy of neuroinflammatory diseases. Front Cell Dev Biol. 2016;4:63.","journal-title":"Front Cell Dev Biol"},{"key":"1111_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2174\/1389450117666160401120514","volume":"18","author":"AN Carvalho","year":"2017","unstructured":"Carvalho AN, Firuzi O, Gama MJ, van Horssen J, Saso L. Oxidative stress and antioxidants in neurological diseases: is there still hope? Curr Drug Targets. 2017;18:705\u201318.","journal-title":"Curr Drug Targets"},{"key":"1111_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1146\/annurev-biochem-061516-045037","volume":"86","author":"H Sies","year":"2017","unstructured":"Sies H, Berndt C, Jones DP. Oxidative stress. Annu Rev Biochem. 2017;86:715\u201348.","journal-title":"Annu Rev Biochem"},{"key":"1111_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1017\/S0007114510003107","volume":"105","author":"F Odabasoglu","year":"2011","unstructured":"Odabasoglu F, Halici Z, Aygun H, Halici M, Atalay F, Cakir A, et al. \u03b1-Lipoic acid has anti-inflammatory and anti-oxidative properties: an experimental study in rats with carrageenan-induced acute and cotton pellet-induced chronic inflammations. Br J Nutr. 2011;105:31\u201343.","journal-title":"Br J Nutr"},{"key":"1111_CR13","doi-asserted-by":"publisher","first-page":"22781","DOI":"10.3390\/ijms160922781","volume":"16","author":"R Uchida","year":"2015","unstructured":"Uchida R, Okamoto H, Ikuta N, Terao K, Hirota T. Enantioselective pharmacokinetics of \u03b1-lipoic acid in rats. Int J Mol Sci. 2015;16:22781\u201394.","journal-title":"Int J Mol Sci"},{"key":"1111_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.pharmthera.2006.07.001","volume":"113","author":"L Holmquist","year":"2007","unstructured":"Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, et al. Lipoic acid as a novel treatment for Alzheimer\u2019s disease and related dementias. Pharmacol Ther. 2007;113:154\u201364.","journal-title":"Pharmacol Ther"},{"key":"1111_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S0165-5728(02)00269-2","volume":"131","author":"GH Marracci","year":"2002","unstructured":"Marracci GH, Jones RE, McKeon GP, Bourdette DN. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;131:104\u201314.","journal-title":"J Neuroimmunol"},{"key":"1111_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1179\/1476830513Y.0000000060","volume":"17","author":"M Khalili","year":"2014","unstructured":"Khalili M, Eghtesadi S, Mirshafiey A, Eskandari G, Sanoobar M, Sahraian MA, et al. Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: a randomized controlled clinical trial. Nutr Neurosci. 2014;17:16\u201320.","journal-title":"Nutr Neurosci"},{"key":"1111_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000356145","volume":"21","author":"M Khalili","year":"2014","unstructured":"Khalili M, Azimi A, Izadi V, Eghtesadi S, Mirshafiey A, Sahraian MA, et al. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: a double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation. 2014;21:291\u20136.","journal-title":"Neuroimmunomodulation"},{"key":"1111_CR18","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1212\/NXI.0000000000000374","volume":"4","author":"R Spain","year":"2017","unstructured":"Spain R, Powers K, Murchison C, Heriza E, Winges K, Yadav V, et al. Lipoic acid in secondary progressive MS: a randomized controlled pilot trial. Neurol Neuroimmunol Neuroinflamm. 2017;4:e374.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1111_CR19","doi-asserted-by":"publisher","first-page":"e49825","DOI":"10.1371\/journal.pone.0049825","volume":"7","author":"P Albrecht","year":"2012","unstructured":"Albrecht P, M\u00fcller A-K, Ringelstein M, Finis D, Geerling G, Cohn E, et al. Retinal neurodegeneration in Wilson\u2019s disease revealed by spectral domain optical coherence tomography. PLoS One. 2012;7:e49825.","journal-title":"PLoS One"},{"key":"1111_CR20","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1177\/1352458512439237","volume":"18","author":"P Albrecht","year":"2012","unstructured":"Albrecht P, Ringelstein M, Muller AK, Keser N, Dietlein T, Lappas A, et al. Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography. Mult Scler. 2012;18:1422\u20139.","journal-title":"Mult Scler"},{"key":"1111_CR21","doi-asserted-by":"publisher","first-page":"e34891","DOI":"10.1371\/journal.pone.0034891","volume":"7","author":"P Albrecht","year":"2012","unstructured":"Albrecht P, Muller A-K, Sudmeyer M, Ferrea S, Ringelstein M, Cohn E, et al. Optical coherence tomography in parkinsonian syndromes. PLoS One. 2012;7:e34891.","journal-title":"PLoS One"},{"key":"1111_CR22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.dadm.2015.03.001","volume":"1","author":"KL Thomson","year":"2015","unstructured":"Thomson KL, Yeo JM, Waddell B, Cameron JR, Pal S. A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. Alzheimers Dement (Amst). 2015;1:136\u201343.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1111_CR23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1177\/1352458515604496","volume":"22","author":"B Knier","year":"2016","unstructured":"Knier B, Berthele A, Buck D, Schmidt P, Zimmer C, M\u00fchlau M, et al. Optical coherence tomography indicates disease activity prior to clinical onset of central nervous system demyelination. Mult Scler. 2016;22:893\u2013900.","journal-title":"Mult Scler"},{"key":"1111_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/WCO.0000000000000327","volume":"29","author":"O Aktas","year":"2016","unstructured":"Aktas O, Albrecht P, Hartung HP. Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. Curr Opin Neurol. 2016;29:199\u2013204.","journal-title":"Curr Opin Neurol"},{"key":"1111_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/2051-5960-2-54","volume":"2","author":"J Groh","year":"2014","unstructured":"Groh J, Stadler D, Buttmann M, Martini R. Non-invasive assessment of retinal alterations in mouse models of infantile and juvenile neuronal ceroid lipofuscinosis by spectral domain optical coherence tomography. Acta Neuropathol Commun. 2014;2:54.","journal-title":"Acta Neuropathol Commun"},{"key":"1111_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jaut.2014.09.003","volume":"56","author":"B Knier","year":"2014","unstructured":"Knier B, Rothhammer V, Heink S, Puk O, Graw J, Hemmer B, Korn T. Neutralizing IL-17 protects the optic nerve from autoimmune pathology and prevents retinal nerve fiber layer atrophy during experimental autoimmune encephalomyelitis. J Autoimmun. 2014;56:34\u201344.","journal-title":"J Autoimmun"},{"key":"1111_CR27","doi-asserted-by":"publisher","first-page":"e96494","DOI":"10.1371\/journal.pone.0096494","volume":"9","author":"A Berger","year":"2014","unstructured":"Berger A, Cavallero S, Dominguez E, Barbe P, Simonutti M, Sahel J-A, et al. Spectral-domain optical coherence tomography of the rodent eye: highlighting layers of the outer retina using signal averaging and comparison with histology. PLoS One. 2014;9:e96494.","journal-title":"PLoS One"},{"key":"1111_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1167\/iovs.11-8092","volume":"53","author":"K Hein","year":"2012","unstructured":"Hein K, Gadjanski I, Kretzschmar B, Lange K, Diem R, S\u00e4ttler MB, B\u00e4hr M. An optical coherence tomography study on degeneration of retinal nerve fiber layer in rats with autoimmune optic neuritis. Invest Ophthalmol Vis Sci. 2012;53:157\u201363.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1111_CR29","doi-asserted-by":"publisher","first-page":"e7507","DOI":"10.1371\/journal.pone.0007507","volume":"4","author":"MD Fischer","year":"2009","unstructured":"Fischer MD, Huber G, Beck SC, Tanimoto N, Muehlfriedel R, Fahl E, et al. Noninvasive, in vivo assessment of mouse retinal structure using optical coherence tomography. PLoS One. 2009;4:e7507.","journal-title":"PLoS One"},{"key":"1111_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1042\/CS20120560","volume":"125","author":"K-C Wang","year":"2013","unstructured":"Wang K-C, Tsai C-P, Lee C-L, Chen S-Y, Lin G-J, Yen M-H, et al. \u03b1-Lipoic acid enhances endogenous peroxisome-proliferator-activated receptor-gamma to ameliorate experimental autoimmune encephalomyelitis in mice. Clin Sci (Lond). 2013;125:329\u201340.","journal-title":"Clin Sci (Lond)"},{"key":"1111_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/1352458509359722","volume":"16","author":"V Yadav","year":"2010","unstructured":"Yadav V, Marracci GH, Munar MY, Cherala G, Stuber LE, Alvarez L, et al. Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters. Mult Scler. 2010;16:387\u201397.","journal-title":"Mult Scler"},{"key":"1111_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jneuroim.2008.05.003","volume":"199","author":"S Salinthone","year":"2008","unstructured":"Salinthone S, Schillace RV, Marracci GH, Bourdette DN, Carr DW. Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells. J Neuroimmunol. 2008;199:46\u201355.","journal-title":"J Neuroimmunol"},{"key":"1111_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.bbi.2007.10.017","volume":"22","author":"RE Jones","year":"2008","unstructured":"Jones RE, Moes N, Zwickey H, Cunningham CL, Gregory WL, Oken B. Treatment of experimental autoimmune encephalomyelitis with alpha lipoic acid and associative conditioning. Brain Behav Immun. 2008;22:538\u201343.","journal-title":"Brain Behav Immun"},{"key":"1111_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jneuroim.2003.11.021","volume":"148","author":"M Morini","year":"2004","unstructured":"Morini M, Roccatagliata L, Dell\u2019Eva R, Pedemonte E, Furlan R, Minghelli S, et al. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004;148:146\u201353.","journal-title":"J Neuroimmunol"},{"key":"1111_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jneuroim.2010.12.002","volume":"233","author":"P Chaudhary","year":"2011","unstructured":"Chaudhary P, Marracci G, Yu X, Galipeau D, Morris B, Bourdette D. Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis. J Neuroimmunol. 2011;233:90\u20136.","journal-title":"J Neuroimmunol"},{"key":"1111_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1742-2094-9-163","volume":"9","author":"P Albrecht","year":"2012","unstructured":"Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012;9:163.","journal-title":"J Neuroinflammation"},{"key":"1111_CR37","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","volume":"86","author":"A Cruz-Herranz","year":"2016","unstructured":"Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86:2303\u20139.","journal-title":"Neurology"},{"key":"1111_CR38","volume":"1","author":"M Dietrich","year":"2017","unstructured":"Dietrich M, Cruz-Herranz A, Yiu H, Aktas O, Brandt AU, Hartung HP, et al. Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide. BMJ Open Ophthalmol. 2017;1:e000008.","journal-title":"BMJ Open Ophthalmol."},{"key":"1111_CR39","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1167\/iovs.04-0541","volume":"45","author":"GT Prusky","year":"2004","unstructured":"Prusky GT, Alam NM, Beekman S, Douglas RM. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis Sci. 2004;45:4611\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1111_CR40","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/S0042-6989(00)00081-X","volume":"40","author":"GT Prusky","year":"2000","unstructured":"Prusky GT, West PW, Douglas RM. Behavioral assessment of visual acuity in mice and rats. Vis Res. 2000;40:2201\u20139.","journal-title":"Vis Res"},{"key":"1111_CR41","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/1352458506070629","volume":"12","author":"KS Shindler","year":"2006","unstructured":"Shindler KS, Guan Y, Ventura E, Bennett J, Rostami A. Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosis. Mult Scler. 2006;12:526\u201332.","journal-title":"Mult Scler"},{"key":"1111_CR42","doi-asserted-by":"publisher","first-page":"723","DOI":"10.4049\/jimmunol.166.2.723","volume":"166","author":"DM Calida","year":"2001","unstructured":"Calida DM, Constantinescu C, Purev E, Zhang GX, Ventura ES, Lavi E, Rostami A. Cutting edge: C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice. J Immunol. 2001;166:723\u20136.","journal-title":"J Immunol"},{"key":"1111_CR43","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.4049\/jimmunol.177.4.2630","volume":"177","author":"G Schreibelt","year":"2006","unstructured":"Schreibelt G, Musters RJP, Reijerkerk A, de Groot LR, van der Pol SMA, Hendrikx EML, et al. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. J Immunol. 2006;177:2630\u20137.","journal-title":"J Immunol"},{"key":"1111_CR44","doi-asserted-by":"crossref","unstructured":"Brookes MH, Golding BT, Howes DA, Hudson AT. Proof that the absolute configuration of natural \u03b1-lipoic acid is R by the synthesis of its enantiomer [(S)-(\u2212)-\u03b1-lipoic acid] from (S)-malic acid. J Chem Soc Chem Commun. 1983;19:1051\u20133.","DOI":"10.1039\/C39830001051"},{"key":"1111_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/(SICI)1520-636X(1997)9:1<32::AID-CHIR7>3.0.CO;2-I","volume":"9","author":"G Niebch","year":"1997","unstructured":"Niebch G, B\u00fcchele B, Blome J, Grieb S, Brandt G, Kampa P, et al. Enantioselective high-performance liquid chromatography assay of (+)R- and (\u2212)S-alpha-lipoic acid in human plasma. Chirality. 1997;9:32\u20136.","journal-title":"Chirality"},{"key":"1111_CR46","first-page":"195","volume":"6","author":"R Hermann","year":"2014","unstructured":"Hermann R, Mungo J, Cnota PJ, Ziegler D. Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms. Clin Pharmacol. 2014;6:195\u2013204.","journal-title":"Clin Pharmacol"},{"key":"1111_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0928-0987(95)00045-3","volume":"4","author":"R Hermann","year":"1996","unstructured":"Hermann R, Niebch G, Borbe HO, Fieger-B\u00fcschges H, Ruus P, Nowak H, et al. Enantioselective pharmacokinetics and bioavailability of different racemic \u03b1-lipoic acid formulations in healthy volunteers. Eur J Pharm Sci. 1996;4:167\u201374.","journal-title":"Eur J Pharm Sci"},{"key":"1111_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s002280050151","volume":"50","author":"CH Gleiter","year":"1996","unstructured":"Gleiter CH, Schug BS, Hermann R, Elze M, Blume HH, Gundert-Remy U. Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur J Clin Pharmacol. 1996;50:513\u20134.","journal-title":"Eur J Clin Pharmacol"},{"key":"1111_CR49","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0006-2952(95)02124-8","volume":"51","author":"GP Biewenga","year":"1996","unstructured":"Biewenga GP, Dorstijn MA, Verhagen JV, Haenen GR, Bast A. Reduction of lipoic acid by lipoamide dehydrogenase. Biochem Pharmacol. 1996;51:233\u20138.","journal-title":"Biochem Pharmacol"},{"key":"1111_CR50","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","volume":"15","author":"R Raftopoulos","year":"2016","unstructured":"Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:259\u201369.","journal-title":"Lancet Neurol"},{"key":"1111_CR51","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/brain\/awr264","volume":"135","author":"SB Syc","year":"2012","unstructured":"Syc SB, Saidha S, Newsome SD, Ratchford JN, Levy M, Ford E, et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain. 2012;135:521\u201333.","journal-title":"Brain"},{"key":"1111_CR52","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1167\/iovs.12-10559","volume":"53","author":"Y Matsunaga","year":"2012","unstructured":"Matsunaga Y, Kezuka T, An X, Fujita K, Matsuyama N, Matsuda R, et al. Visual functional and histopathological correlation in experimental autoimmune optic neuritis. Invest Ophthalmol Vis Sci. 2012;53:6964\u201371.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1111_CR53","first-page":"1503","volume":"22","author":"CM Larabee","year":"2016","unstructured":"Larabee CM, Desai S, Agasing A, Georgescu C, Wren JD, Axtell RC, Plafker SM. Loss of Nrf2 exacerbates the visual deficits and optic neuritis elicited by experimental autoimmune encephalomyelitis. Mol Vis. 2016;22:1503\u201313.","journal-title":"Mol Vis"},{"key":"1111_CR54","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jnc.13770","volume":"139","author":"AW Smith","year":"2016","unstructured":"Smith AW, Rohrer B, Wheless L, Samantaray S, Ray SK, Inoue J, et al. Calpain inhibition reduces structural and functional impairment of retinal ganglion cells in experimental optic neuritis. J Neurochem. 2016;139:270\u201384.","journal-title":"J Neurochem"},{"key":"1111_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.neulet.2012.08.016","volume":"526","author":"B Liu","year":"2012","unstructured":"Liu B, Ma X, Guo D, Guo Y, Chen N, Bi H. Neuroprotective effect of alpha-lipoic acid on hydrostatic pressure-induced damage of retinal ganglion cells in vitro. Neurosci Lett. 2012;526:24\u20138.","journal-title":"Neurosci Lett"},{"key":"1111_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.brainres.2012.12.041","volume":"1499","author":"Y Koriyama","year":"2013","unstructured":"Koriyama Y, Nakayama Y, Matsugo S, Kato S. Protective effect of lipoic acid against oxidative stress is mediated by Keap1\/Nrf2-dependent heme oxygenase-1 induction in the RGC-5 cellline. Brain Res. 2013;1499:145\u201357.","journal-title":"Brain Res"},{"key":"1111_CR57","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/10715760290029155","volume":"36","author":"J Flier","year":"2002","unstructured":"Flier J, van Muiswinkel FL, Jongenelen CAM, Drukarch B. The neuroprotective antioxidant alpha-lipoic acid induces detoxication enzymes in cultured astroglial cells. Free Radic Res. 2002;36:695\u20139.","journal-title":"Free Radic Res"},{"key":"1111_CR58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0891-5849(95)00017-R","volume":"19","author":"L Packer","year":"1995","unstructured":"Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227\u201350.","journal-title":"Free Radic Biol Med"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-018-1111-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T21:57:44Z","timestamp":1603922264000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-018-1111-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1111"],"URL":"https:\/\/doi.org\/10.1186\/s12974-018-1111-y","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"23 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All protocols involving animals were compliance with the experimental guidelines approved by the regional authorities (State Agency for Nature, Environment and Consumer Protection) and conform to the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. The following financial disclosures are unrelated to the work: Michael Dietrich received speaker honoraria from Novartis. Carsten Berndt received research support from Biogen. Patrick K\u00fcry performed consultancy work for Geneuro. Orhan Aktas received grants from the German Research Foundation (DFG) and the German Ministry of Education and Research (BMBF); grants and personal fees from Bayer HealthCare, Biogen, Genzyme, Novartis, and Teva; and personal fees from Almirall, MedImmune, Merck Serono, and Roche. Hans-Peter Hartung has received fees for serving on steering committees from Biogen Idec, GeNeuro, Sanofi Genzyme, Merck, Novartis Pharmaceuticals, Octapharma, Opexa Therapeutics, Teva Pharmaceuticals, MedImmune, Bayer HealthCare, Forward Pharma, and Roche; fees for serving on advisory boards from Biogen Idec, Sanofi Genzyme, Merck, Novartis Pharmaceuticals, Octapharma, Opexa Therapeutics, Teva Pharmaceuticals, and Roche; and lecture fees from Biogen Idec, Sanofi Genzyme, Merck, Novartis Pharmaceuticals, Octapharma, Opexa Therapeutics, Teva Pharmaceuticals, MedImmune, and Roche. Philipp Albrecht received compensation for serving on Scientific Advisory Boards for Ipsen, Novartis, and Biogen; he received speaker honoraria and travel support from Novartis, Teva, Biogen, Merz Pharmaceuticals, Ipsen, Allergan, Bayer Healthcare, Esai, UCB, and Glaxo Smith Kline; he received research support from Novartis, Biogen, Teva, Merz Pharmaceuticals, Ipsen, and Roche. The other authors report no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"71"}}